<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559128</url>
  </required_header>
  <id_info>
    <org_study_id>G 15-06-02</org_study_id>
    <nct_id>NCT02559128</nct_id>
  </id_info>
  <brief_title>The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes</brief_title>
  <acronym>CARMET2</acronym>
  <official_title>The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this cross-sectional comparative 2x2 trial study is to compare the degree of&#xD;
      insulin resistance, myocardial function and selected metabolic parameters and to explore the&#xD;
      pathophysiological mechanisms by which insulin resistance is implicated in development of&#xD;
      chronic heart failure (HF) in patients with type 2 diabetes and prediabetes (T2D).&#xD;
&#xD;
      Investigators hypothesize that patients with heart failure will be insulin-resistant and will&#xD;
      display metabolic abnormalities as patients with diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 subjects in total, divided into four groups will be included: 40 patients with type 2&#xD;
      diabetes or prediabetes and chronic HF without previous pharmacological treatment (T2D+HF+),&#xD;
      20 subjects with HF without T2D (HF+T2D-), 20 subjects with T2D alone (HF-T2D+) and 20&#xD;
      healthy control volunteers (HF-T2D-).&#xD;
&#xD;
      All examinations will be done during a short admission at Diabetes Center (CD) in Institute&#xD;
      for Clinical and Experimental Medicine (IKEM), always under comparable circumstances. All&#xD;
      participants will undergo standardized selection of metabolic and cardiovascular tests.&#xD;
&#xD;
      Oxidative stress markers, selected cytokines, peptides and metabolites in blood and&#xD;
      subcutaneous adipose tissue will be analyzed. Investigators assume that this project will&#xD;
      bring new knowledge which will contribute to discovery of the mechanisms implicated in the&#xD;
      development of heart failure in patients with type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>At baseline</time_frame>
    <description>Difference in glucose disposal rate and metabolic clearance rate of glucose measured by hyperinsulinemic euglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart function</measure>
    <time_frame>At baseline</time_frame>
    <description>Difference in left ventricular ejection fraction (LV EF), diastolic function (E/E´, left atrial volume) and ventriculi-vascular coupling measured by non-invasive estimation of end-systolic left ventricular (Ees) and arterial elastance (Ea) by single beat method measured by ECHO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>At baseline</time_frame>
    <description>Difference in peak oxygen consumption (peak VO2) and chronotropy index measured by symptom-limited bicycle spiroergometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota spectrum in stool and gut microbe generated trimethylamine N-oxide (TMAO) in plasma</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change in digital pulse amplitude tonometry from the basal state before the clamp and at the end f the measurement</time_frame>
    <description>Change in endothelial function by acute artificial hyperinsulinemia measured by digital pulse tonometry during hyperinsulinemic euglycemic clamp</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>HF+T2D+</arm_group_label>
    <description>40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF+T2D-</arm_group_label>
    <description>20 subjects with HF without T2D or prediabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF-T2D+</arm_group_label>
    <description>20 subjects with T2D or prediabetes alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF-T2D-</arm_group_label>
    <description>20 healthy control volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        100 subjects in total, divided into four groups will be included: 40 patients with type 2&#xD;
        diabetes or prediabetes and chronic heart failure (HF+T2D+), 20 subjects with HF without&#xD;
        T2D (HF+T2D-), 20 subjects with T2D alone (HF-T2D+) and 20 healthy control volunteers&#xD;
        (HF-T2D-).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A. For group HF+T2D+&#xD;
&#xD;
          1. Chronic heart failure will be defined by the following criteria (all must be&#xD;
             included):&#xD;
&#xD;
               -  diagnosis of HF known for at least 6 months&#xD;
&#xD;
               -  medical history of hospitalization for cardiac decompensation with need for&#xD;
                  parenteral therapy for congestion - X-ray findings or swelling of lower&#xD;
                  extremities&#xD;
&#xD;
               -  stable drug therapy at least 1 month&#xD;
&#xD;
               -  treatment with diuretics (thiazide or furosemide)&#xD;
&#xD;
               -  left ventricular ejection fraction (LVEF) below 50%&#xD;
&#xD;
          2. The presence of diabetes/prediabetes will be defined by:&#xD;
&#xD;
               -  diagnosis and treatment of type 2 diabetes in the medical history&#xD;
&#xD;
               -  or estimated screening blood sample: values of HbA1c (according to IFCC) ≥39&#xD;
                  mmol/mol for prediabetes, ≥48 for diabetes and fasting plasma glucose level ≥5.6&#xD;
                  mmol/l for prediabetes and ≥7 mmol/l for diabetes or ≥7.8 mmol/l for prediabetes&#xD;
                  and ≥11.1 mmol/l for diabetes according to oral glucose tolerance test (oGTT).&#xD;
&#xD;
               -  treatment of diabetes - by diet only&#xD;
&#xD;
               -  women and men aged 40-70 years&#xD;
&#xD;
               -  body mass index (kg/m2) in the range of 20-35&#xD;
&#xD;
               -  the range of HbA1c between 40-65 mmol/mol (IFCC)&#xD;
&#xD;
               -  signed informed consent&#xD;
&#xD;
        B.For group HF+T2D-&#xD;
&#xD;
        Chronic heart failure will be defined by the following criteria (all must be included):&#xD;
&#xD;
          -  diagnosis of HF known for at least 6 months&#xD;
&#xD;
          -  medical history of hospitalization for cardiac decompensation with need for parenteral&#xD;
             therapy for congestion - X-ray findings or swelling of lower extremities&#xD;
&#xD;
          -  stable drug therapy at least 1 month&#xD;
&#xD;
          -  treatment with diuretics (thiazide or furosemide)&#xD;
&#xD;
          -  LVEF below 50%&#xD;
&#xD;
          -  no history of diabetes, HbA1c &lt;39 mmol/mol (IFCC) and fasting plasma glucose level&#xD;
             under 5.6 mmol/l&#xD;
&#xD;
          -  women and men aged 40-70 years&#xD;
&#xD;
          -  body mass index (kg/m2) in the range of 20-35&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        C.For group HF-T2D+&#xD;
&#xD;
        The presence of diabetes/prediabetes will be defined by:&#xD;
&#xD;
          -  diagnosis and treatment of type 2 diabetes in the medical history&#xD;
&#xD;
          -  or estimated screening blood sample: values of HbA1c (according to IFCC) ≥39 mmol/mol&#xD;
             for prediabetes, ≥48 for diabetes and fasting plasma glucose level ≥5.6 mmol/l for&#xD;
             prediabetes and ≥7 mmol/l for diabetes or ≥7.8 mmol/l for prediabetes and ≥11.1 mmol/l&#xD;
             for diabetes according to oGTT&#xD;
&#xD;
          -  treatment of diabetes - by diet only&#xD;
&#xD;
          -  women and men aged 40-70 years&#xD;
&#xD;
          -  body mass index (kg/m2) in the range of 20-35&#xD;
&#xD;
          -  the range of HbA1c between 40-65 mmol/mol (IFCC)&#xD;
&#xD;
          -  no history of acute or chronic heart disease&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        D.For group HF-T2D-&#xD;
&#xD;
        Absence of metabolic syndrome (not more than any two of the following symptoms):&#xD;
&#xD;
          -  abdominal obesity - waist circumference in men&gt; 102 cm, in women &gt; 88 cm&#xD;
&#xD;
          -  diagnosis and treatment of type 2 diabetes or raised fasting plasma glucose level&#xD;
             (FPG&gt; 5,6 mmol/l)&#xD;
&#xD;
          -  raised blood pressure (BP): systolic BP &gt; 130 mm Hg or diastolic BP &gt;85 mm Hg, or&#xD;
             treatment of previously diagnosed hypertension&#xD;
&#xD;
          -  reduced HDL cholesterol in men &lt; 1 mmol/l, in women &lt; 1,3 mmol/l (or treatment)&#xD;
&#xD;
          -  raised triglycerides &gt; 1,7 mmol/l (or treatment)&#xD;
&#xD;
          -  absence of chronic or acute cardiovascular disease&#xD;
&#xD;
          -  women and men aged 40-70 years&#xD;
&#xD;
          -  body mass index (kg/m2) in the range of 20-35&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria groups (A+B+C+D):&#xD;
&#xD;
          -  metabolic disease, including: 1 type diabetes, decompensated thyreopathy (Note:&#xD;
             patients with hypothyroidism and stable substitution (the last 3 months) of normal&#xD;
             thyrotropic-stimulating hormone levels may participate in the study)&#xD;
&#xD;
          -  pregnancy (positive human chorionic gonadotropin test), breast feeding, trying to&#xD;
             become pregnant&#xD;
&#xD;
          -  clinically significant anemia with hemoglobin below 100 g/l&#xD;
&#xD;
          -  renal insufficiency with estimated glomerular filtration under 0.7 ml/s&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  alcoholism or drug use&#xD;
&#xD;
          -  the presence of other medical condition, which occurs during physical examination,&#xD;
             laboratory tests, ECG, including pulmonary, neurological or inflammatory disease,&#xD;
             which would be considered by the examiner to distort the consistency of data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terezie Pelikánová, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiří Veleba, MD</last_name>
    <phone>+420 261 364 100</phone>
    <email>jiri.veleba@medicon.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terezie Pelikánová, Prof., MD</last_name>
    <phone>+420 261 364 100</phone>
    <email>terezie.pelikanova@medicon.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <state>Prague 4</state>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terezie Pelikanova, Prof., MD</last_name>
      <phone>+420 261 364 100</phone>
      <email>terezie.pelikanova@medicon.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Terezie Pelikanova</investigator_full_name>
    <investigator_title>Prof. Terezie Pelikánová, MD.,PhD.</investigator_title>
  </responsible_party>
  <keyword>Insulin Resistance</keyword>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

